Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 21 to 30 of 220 total matches.

Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
% vs 11.4% with (randomized, open-label, chemotherapy (p=0.001) phase 3, n=542) DOR: NR PFS: 2.1 mos ...
The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):e202-3 |  Show IntroductionHide Introduction

Autologous Bone marrow Transplantation For Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 03, 1991  (Issue 843)
chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously — is being ...
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Med Lett Drugs Ther. 1991 May 3;33(843):39-40 |  Show IntroductionHide Introduction

Cemiplimab (Libtayo) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
chemotherapy than with chemotherapy alone (21.9 vs 13.0 months). Median progression-free survival was 8.2 ...
The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations and who are not candidates for surgical resection or chemoradiation. The drug was previously approved for first-line treatment of NSCLC in patients whose tumors have high PD-L1 expression and no genomic tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8   doi:10.58347/tml.2023.1674e |  Show IntroductionHide Introduction

Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
or GEJ adenocarcinoma, addition of zolbetuximab to standard chemotherapy extended progression-free ...
Zolbetuximab-clzb (Vyloy – Astellas), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, has been approved by the FDA for use in combination with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have CLDN18.2-positive tumors. It is the first monoclonal antibody to be approved in the US that selectively targets CLDN18.2.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e204-5   doi:10.58347/tml.2024.1717g |  Show IntroductionHide Introduction

Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017  (Issue 1515)
(NSCLC) that have progressed during or following platinum-based chemotherapy. Atezolizumab is the first ...
The FDA has approved the immune checkpoint inhibitor atezolizumab (Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC) that have progressed during or following platinum-based chemotherapy. Atezolizumab is the first programmed death-ligand 1 (PD-L1) blocking antibody to become available in the US. Two other immune checkpoint inhibitors, the programmed death receptor-1 (PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda), are also approved for treatment of metastatic NSCLC, and...
Med Lett Drugs Ther. 2017 Feb 27;59(1515):e40-1 |  Show IntroductionHide Introduction

Capecitabine and Trastuzumab for Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 1998  (Issue 1039)
using trastuzumab alone in patients refractory to chemotherapy, or with paclitaxel (Taxol) for first ...
Trastuzumab (Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral pro-drug for 5-fluorouracil, have been approved by the FDA for treatment of metastatic breast cancer.
Med Lett Drugs Ther. 1998 Nov 6;40(1039):106-8 |  Show IntroductionHide Introduction

Gemtuzumab for Relapsed Acute Myeloid Leukemia

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000  (Issue 1083)
years old and may not be able to tolerate cytotoxic chemotherapy. TREATMENT OF AML — Conventional ...
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy
Med Lett Drugs Ther. 2000 Jul 24;42(1083):67-8 |  Show IntroductionHide Introduction

Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024  (Issue 1694)
chemotherapy. It is the first immune checkpoint inhibitor to be approved in the US for treatment ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin and gemcitabine for first-line treatment of recurrent locally advanced or metastatic nasopharyngeal carcinoma and for use as monotherapy for treatment of recurrent unresectable or metastatic nasopharyngeal carcinoma in adults with disease progression on or after platinum-based chemotherapy. It is the first immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7   doi:10.58347/tml.2024.1694e |  Show IntroductionHide Introduction

Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease ...
The FDA has approved datopotamab deruxtecan (Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2   doi:10.58347/tml.2025.1723e |  Show IntroductionHide Introduction

Ramucirumab (Cyramza) for Gastric and GEJ Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
(GEJ) adenocarcinoma that has progressed on or after platinum- or fluoropyrimidine-based chemotherapy ...
Ramucirumab (Cyramza – Lilly), a monoclonal antibody that inhibits vascular endothelial growth factor receptor 2 (VEGFR2), has been approved by the FDA for use as monotherapy or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after platinum- or fluoropyrimidine-based chemotherapy. Ramucirumab is also approved for use in combination with docetaxel (Taxotere, and others) for treatment of metastatic non-small cell lung cancer that has progressed on or after platinum-based...
Med Lett Drugs Ther. 2015 May 11;57(1468):74-5 |  Show IntroductionHide Introduction